全文获取类型
收费全文 | 918篇 |
免费 | 44篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 46篇 |
妇产科学 | 11篇 |
基础医学 | 76篇 |
口腔科学 | 9篇 |
临床医学 | 96篇 |
内科学 | 118篇 |
皮肤病学 | 1篇 |
神经病学 | 212篇 |
特种医学 | 170篇 |
外科学 | 62篇 |
综合类 | 18篇 |
预防医学 | 39篇 |
眼科学 | 12篇 |
药学 | 59篇 |
肿瘤学 | 61篇 |
出版年
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 9篇 |
2016年 | 7篇 |
2015年 | 10篇 |
2014年 | 16篇 |
2013年 | 24篇 |
2012年 | 22篇 |
2011年 | 25篇 |
2010年 | 21篇 |
2009年 | 14篇 |
2008年 | 18篇 |
2007年 | 33篇 |
2006年 | 23篇 |
2005年 | 26篇 |
2004年 | 22篇 |
2003年 | 22篇 |
2002年 | 19篇 |
2001年 | 19篇 |
2000年 | 10篇 |
1999年 | 17篇 |
1998年 | 33篇 |
1997年 | 32篇 |
1996年 | 41篇 |
1995年 | 23篇 |
1994年 | 19篇 |
1993年 | 26篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 25篇 |
1989年 | 26篇 |
1988年 | 38篇 |
1987年 | 36篇 |
1986年 | 27篇 |
1985年 | 26篇 |
1984年 | 12篇 |
1983年 | 12篇 |
1982年 | 21篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1977年 | 14篇 |
1976年 | 25篇 |
1975年 | 14篇 |
1974年 | 13篇 |
1973年 | 14篇 |
1972年 | 11篇 |
1971年 | 12篇 |
1970年 | 9篇 |
1969年 | 11篇 |
排序方式: 共有990条查询结果,搜索用时 15 毫秒
31.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献
32.
An antibody (DIL) from a patient with idiopathic thrombocytopenic purpura (ITP) was shown to have autospecificity on the basis of reactions with autologous platelets that were identical to those obtained with platelets from normal subjects. DIL antibody also reacted strongly in an immunofluorescence test with platelets from a patient with Glanzmann's thrombasthenia, but failed to react with platelets from a patient with the Bernard-Soulier syndrome who was known to be deficient in glycoprotein Ib (GPIb). Purified GPIb and control platelets, but not Bernard-Soulier platelets, inhibited the lytic activity of DIL. Using the GPIb-specific monoclonal antibody AP1 and one-dimensional rocket electrophoresis into gels containing rabbit antihuman platelet membrane antibody, it was shown that staphylococcal protein A-Sepharose beads coated with DIL antibody selectively remove GPIb from solubilized platelet preparations. By crossed immunoelectrophoresis it was found that DIL recognizes a determinant on GPIb on the membrane side of the cleavage site of the platelet calcium- activated protease (calpain). These studies provide direct evidence for binding of a platelet autoantibody to a determinant on GPIb relatively close to the site of insertion of this protein into the platelet membrane. 相似文献
33.
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C 总被引:1,自引:1,他引:1 下载免费PDF全文
P A Wender C M Cribbs K F Koehler N A Sharkey C L Herald Y Kamano G R Pettit P M Blumberg 《Proceedings of the National Academy of Sciences of the United States of America》1988,85(19):7197-7201
The bryostatins are macrocyclic lactones that represent an additional structural class of potent activators of protein kinase C. These marine animal biosynthetic products are of unusual interest because they induce only a subset of the biological responses induced by the phorbol esters. We have now determined the binding affinities of naturally occurring and semisynthetic bryostatins for protein kinase C by competition analysis with [26-3H]bryostatin 4 as the radioactive ligand. Esterification of the hydroxyl group at C26 caused dramatic loss of activity as did inversion of the asymmetric center at this position. In contrast, neither of the ester groups at C7 and C20 had a major influence on activity. Computer modeling of the phorbol esters, related diterpenes, and indole alkaloids suggested that the C20, C9, and C4 oxygens of phorbol represented critical elements of the phorbol ester pharmacophore. The C26 oxygen of the bryostatins, together with the C1 and C19 oxygens, gave an excellent spatial correlation with this model, with a root-mean-square deviation of 0.16 A (compared to 0.10-0.35 A among phorbol-related diterpenes). The extension of the phorbol ester pharmacophore model to the bryostatins and its agreement with the structure-activity relations for the bryostatin class of compounds provide additional support for the validity of the model. 相似文献
34.
35.
36.
37.
David RH Christie Kenneth W Tiver 《Journal of Medical Imaging and Radiation Oncology》1996,40(3):331-333
Five patients who received radiotherapy (RT) for 7 melanotic freckles (MF, also known as Hutchinson's freckles, lentigo maligna) were reviewed 8 to 37 months after their treatment by RT. Local control and a favourable cosmetic result occurred in all patients. Treatment toxicity was minimal. Few reports about the use of RT for MF exist. Many other treatments including observation alone have been associated with high rates of recurrence, and in some cases conversion to invasive melanoma has occurred. RT appears to be a safe and effective treatment for this condition, providing that doses equivalent to 44 Gy in 11 fractions or more are given. 相似文献
38.
Wender M 《Neurologia i neurochirurgia polska》2003,37(4):777-782
Early immunomodulatory treatment of multiple sclerosis has raised great hopes, especially among MS patients and their families. However, there are considerable differences of opinion among medical professionals, particularly as regards the economic aspect of the therapy (often undertaken before any definite diagnosis is made). The findings documenting early irreversible axonal lesions and brain atrophy in MS, as well as results of clinical studies suggest that early immunomodulatory treatment is the method of choice, even if critical arguments are taken into account. 相似文献
39.
40.